Sign in
PCSA Stock Price, Chart, Stats & News
Processa Pharmaceuticals, Inc.
Save
Processa Pharmaceuticals, Inc. (PCSA) does not currently pay a dividend.
5.20M
Market cap
–
Current P/E
–
Forward P/E
PCSA chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -173.59% |
ROE | -257.81% |
D/E | – |
Interest coverage ratio | – |
PCSA valuation
P/E | – |
P/S | – |
P/B | 1.12x |
P/CF | -0.44x |
P/FCF | -0.39x |
P/OCF | -0.44x |
PEG | -1.89x |
EV multiple | – |
About
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition.
Similar securities
Based on sector and market capitalization
Report issue